Interferon omega

Drug Profile

Interferon omega

Alternative Names: IFN-omega; Interferon-omega; ITCA-638; Omega DUROS interferon therapy; Omega-interferon

Latest Information Update: 11 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Intarcia Therapeutics
  • Class Antivirals; Interferons
  • Mechanism of Action Immunostimulants; Interferon type I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer; Hepatitis C

Most Recent Events

  • 16 Apr 2007 Final results from a phase II clinical trial in patients with hepatitis C added to the adverse events and Viral Infections therapeutic trials sections
  • 10 Jun 2005 Data presented at the 18th International Conference on Antiviral Research (ICAR-2005) have been added to the Adverse Events and Viral Infections antimicrobial activity sections
  • 30 Nov 2004 Phase-II clinical trials in Hepatitis C in Russia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top